{"id":"W4226374363","doi":"","title":"Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors","year":2022,"lang":"en","type":"article","venue":"EUR Research Repository (Erasmus University Rotterdam)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Cancer Foundation; Princess Margaret Cancer Centre","funders":"Ono Pharmaceutical; Università degli Studi di Milano; Bristol-Myers Squibb","keywords":"Tolerability; Nivolumab; Medicine; Adverse effect; Internal medicine; Dosing; Phases of clinical research; Pharmacology; Gastroenterology; Mesothelin; Pharmacodynamics; Oncology; Clinical trial; Cancer; Pharmacokinetics; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008305106,0.00155481,0.002037733,0.0004720612,0.0003492559,0.001225793,0.0006117445,0.0009548909,0.007589262],"category_scores_gemma":[0.0005536814,0.000521683,0.00151334,0.0004454513,0.0007187983,0.000904025,0.0003075366,0.002092187,0.002169857],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009077508,"about_ca_system_score_gemma":0.001005444,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009787556,"about_ca_topic_score_gemma":0.002819127,"domain_scores_codex":[0.9997819,0.00008179942,0.0000144438,0.00004439526,0.000022995,0.00005446917],"domain_scores_gemma":[0.9997446,0.0000304415,0.00005410732,0.00001971101,0.00001490101,0.0001362673],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7920401,0.01441343,0.003121187,0.002838809,0.003004988,0.0002464927,0.0001965192,0.002460634,0.02651774,0.0005542497,0.01335184,0.141254],"study_design_scores_gemma":[0.7822435,0.1948824,0.009693765,0.000164696,0.001234877,0.0002553073,0.00008092556,0.001160536,0.002519414,0.0005285179,0.007202795,0.00003310105],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9555589,0.01663552,0.0009863917,0.002065152,0.0009263558,0.004394675,0.004947464,0.0003679405,0.01411761],"genre_scores_gemma":[0.967482,0.008063614,0.001536916,0.001669186,0.0004453482,0.002208238,0.005775657,0.00006882498,0.01275024],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007589262,"threshold_uncertainty_score":0.0253886,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02240105381484284,"score_gpt":0.3279784093321598,"score_spread":0.3055773555173169,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}